Axsome Therapeutics Inc
General ticker "AXSM" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $4.2B
Axsome Therapeutics Inc follows the US Stock Market performance with the rate: 39.8%.
Estimated limits based on current volatility of 4.2%: low 86.63$, high 94.19$
Factors to consider:
- Current price 65.5% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [37.26$, 83.56$]
- 2024-12-30 to 2025-12-30 estimated range: [23.27$, 56.60$]
Financial Metrics affecting the AXSM estimates:
- Negative: Non-GAAP EPS, $ of -3.27 <= 0.10
- Negative: Operating profit margin, % of -46.14 <= 1.03
- Negative: Operating cash flow per share per price, % of -4.32 <= 2.35
- Positive: Interest expense per share, $ of 0.14 <= 0.74
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -12.63 <= 3.85
Short-term AXSM quotes
Long-term AXSM plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $50.04MM | $270.60MM |
| Operating Expenses | $124.71MM | $226.54MM | $502.43MM |
| Operating Income | $-124.71MM | $-176.50MM | $-231.82MM |
| Non-Operating Income | $-5.70MM | $-10.63MM | $-6.45MM |
| Interest Expense | $5.70MM | $7.33MM | $6.45MM |
| R&D Expense | $58.06MM | $57.95MM | $97.94MM |
| Income(Loss) | $-130.40MM | $-187.13MM | $-238.28MM |
| Taxes | $0.00MM | $10.63MM | $0.96MM |
| Profit(Loss) | $-130.40MM | $-197.77MM | $-239.24MM |
| Stockholders Equity | $15.63MM | $109.56MM | $190.98MM |
| Inventory | $0.00MM | $4.32MM | $15.13MM |
| Assets | $87.79MM | $331.48MM | $588.24MM |
| Operating Cash Flow | $-108.23MM | $-116.51MM | $-145.08MM |
| Capital expenditure | $0.31MM | $0.70MM | $0.58MM |
| Investing Cash Flow | $-0.31MM | $-53.70MM | $-0.58MM |
| Financing Cash Flow | $11.13MM | $284.58MM | $331.01MM |
| Earnings Per Share* | $-3.59 | $-4.86 | $-5.27 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.